Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

COX-2 modulates mammary tumor progression in response to collagen density.

Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L, Keely P.

Breast Cancer Res. 2016 Mar 22;18(1):35. doi: 10.1186/s13058-016-0695-3.

2.

Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: From experimental models to clinical trials.

Maru GB, Hudlikar RR, Kumar G, Gandhi K, Mahimkar MB.

World J Biol Chem. 2016 Feb 26;7(1):88-99. doi: 10.4331/wjbc.v7.i1.88. Review.

3.

Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China.

Fang JY, Zheng S, Jiang B, Lai MD, Fang DC, Han Y, Sheng QJ, Li JN, Chen YX, Gao QY.

Gastrointest Tumors. 2014 Jun;1(2):53-75. doi: 10.1159/000362585. Epub 2014 May 9.

4.

Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression.

Stamatakis K, Jimenez-Martinez M, Jimenez-Segovia A, Chico-Calero I, Conde E, Galán-Martínez J, Ruiz J, Pascual A, Barrocal B, López-Pérez R, García-Bermejo ML, Fresno M.

Oncotarget. 2015 Nov 24;6(37):39941-59. doi: 10.18632/oncotarget.5402.

5.

The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis.

Rynne-Vidal A, Jiménez-Heffernan JA, Fernández-Chacón C, López-Cabrera M, Sandoval P.

Cancers (Basel). 2015 Sep 29;7(4):1994-2011. doi: 10.3390/cancers7040872. Review.

6.

Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography.

LeGendre-McGhee S, Rice PS, Wall RA, Sprute KJ, Bommireddy R, Luttman AM, Nagle RB, Abril ER, Farrell K, Hsu CH, Roe DJ, Gerner EW, Ignatenko NA, Barton JK.

Cancer Growth Metastasis. 2015 Sep 7;8(Suppl 1):63-80. doi: 10.4137/CGM.S21216. eCollection 2015.

7.

Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk.

Davenport JR, Cai Q, Ness RM, Milne G, Zhao Z, Smalley WE, Zheng W, Shrubsole MJ.

Mol Carcinog. 2016 Aug;55(8):1251-61. doi: 10.1002/mc.22367. Epub 2015 Aug 31.

PMID:
26333108
8.

Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles.

Ma Y, Gao S, Hu M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 15;1001:202-11. doi: 10.1016/j.jchromb.2015.07.026. Epub 2015 Jul 19.

9.

Role of the Aryl Hydrocarbon Receptor in Colon Neoplasia.

Xie G, Raufman JP.

Cancers (Basel). 2015 Jul 31;7(3):1436-46. doi: 10.3390/cancers7030847.

10.

Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

Carethers JM, Jung BH.

Gastroenterology. 2015 Oct;149(5):1177-1190.e3. doi: 10.1053/j.gastro.2015.06.047. Epub 2015 Jul 26. Review.

PMID:
26216840
11.

Enhancing adherence in trials promoting change in diet and physical activity in individuals with a diagnosis of colorectal adenoma; a systematic review of behavioural intervention approaches.

McCahon D, Daley AJ, Jones J, Haslop R, Shajpal A, Taylor A, Wilson S, Dowswell G.

BMC Cancer. 2015 Jul 7;15:505. doi: 10.1186/s12885-015-1502-8. Review.

12.

Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.

Papanagnou P, Baltopoulos P, Tsironi M.

Ther Clin Risk Manag. 2015 May 18;11:807-19. doi: 10.2147/TCRM.S82049. eCollection 2015. Review.

13.

Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression.

Yao L, Han C, Song K, Zhang J, Lim K, Wu T.

Cancer Res. 2015 Apr 1;75(7):1388-98. doi: 10.1158/0008-5472.CAN-14-2561. Epub 2015 Feb 17.

14.

Effects of supplemental vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasms.

Bostick RM.

J Steroid Biochem Mol Biol. 2015 Apr;148:86-95. doi: 10.1016/j.jsbmb.2015.01.010. Epub 2015 Jan 15. Review.

15.

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS.

J Natl Cancer Inst. 2014 Nov 27;107(1):345. doi: 10.1093/jnci/dju345. Print 2015 Jan.

16.

Primary prevention of colorectal cancer: myth or reality?

Crosara Teixeira M, Braghiroli MI, Sabbaga J, Hoff PM.

World J Gastroenterol. 2014 Nov 7;20(41):15060-9. doi: 10.3748/wjg.v20.i41.15060. Review.

17.

Chemoprevention in patients with genetic risk of colorectal cancers.

Laukaitis CM, Erdman SH, Gerner EW.

Colorectal Cancer. 2012;1(3):225-240.

18.

Primary and secondary prevention of colorectal cancer.

Tárraga López PJ, Albero JS, Rodríguez-Montes JA.

Clin Med Insights Gastroenterol. 2014 Jul 14;7:33-46. doi: 10.4137/CGast.S14039. eCollection 2014. Review.

19.

CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.

Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, Holla VR, Yang P, DuBois RN.

Invest New Drugs. 2014 Dec;32(6):1105-12. doi: 10.1007/s10637-014-0144-z. Epub 2014 Aug 3.

20.

Case-control study of aspirin use and risk of pancreatic cancer.

Streicher SA, Yu H, Lu L, Kidd MS, Risch HA.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1254-63. doi: 10.1158/1055-9965.EPI-13-1284.

Items per page

Supplemental Content

Write to the Help Desk